We are live on ! Find out more
JGC

J. Goldman & Co Portfolio holdings

AUM $3.44B
1-Year Est. Return 33.8%
This Fund
S&P 500
This Quarter Est. Return
+10.45%
1 Year Est. Return
+33.8%
3 Year Est. Return
+89.45%
5 Year Est. Return
+82.14%
10 Year Est. Return
+407.39%
AUM
$3.1B
AUM Growth
+$632M
Cap. Flow
+$447M
Cap. Flow %
14.4%
Top 10 Hldgs %
19.97%
Holding
560
New
236
Increased
69
Reduced
84
Closed
160

Top Buys

Rank Stock Value
1
EBAY icon
eBay
EBAY
+$59.6M
2
SHW icon
Sherwin-Williams
SHW
+$57.5M
3
BBY icon
Best Buy
BBY
+$44.8M
4
SBAC icon
SBA Communications
SBAC
+$43.9M
5
NKE icon
Nike
NKE
+$36.3M

Top Sells

Rank Stock Value
1
PYPL icon
PayPal
PYPL
+$67.6M
2
MSFT icon
Microsoft
MSFT
+$45.7M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$37.1M
4
MDU icon
MDU Resources
MDU
+$36.5M
5
BA icon
Boeing
BA
+$29.8M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 18.29%
2 Technology 12.47%
3 Industrials 10.27%
4 Healthcare 7.4%
5 Communication Services 6.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TRVI icon
326
Trevi Therapeutics
TRVI
$2.66B
$476K 0.02%
137,873
ACVA icon
327
ACV Auctions
ACVA
$1.4B
$459K 0.01%
+24,458
New +$383K
LOVE
328
LoveSac
LOVE
$266M
$456K 0.01%
+20,194
New +$471K
TCOM icon
329
Trip.com Group
TCOM
$29.5B
$451K 0.01%
+10,269
New +$417K
TPIC
330
CALL
DELISTED
TPI Composites
TPIC
$437K 0.01%
+150,000
New +$442K
CCL icon
331
Carnival Corporation Ltd
CCL
$40.5B
$429K 0.01%
+26,244
New +$427K
WING icon
332
Wingstop
WING
$3.31B
$427K 0.01%
1,166
-44
-4% -$13.7K
DCPH
333
PUT
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$425K 0.01%
+27,000
New +$416K
CPRX
334
DELISTED
Catalyst Pharmaceutical
CPRX
$421K 0.01%
26,392
-349
-1% -$5.26K
LCII icon
335
LCI Industries
LCII
$2.6B
$415K 0.01%
+3,373
New +$397K
IOVA icon
336
PUT
Iovance Biotherapeutics
IOVA
$1.95B
$400K 0.01%
+27,000
New +$314K
REAL icon
337
PUT
The RealReal
REAL
$1.53B
$391K 0.01%
+100,000
New +$238K
EVER icon
338
EverQuote
EVER
$844M
$383K 0.01%
+20,628
New +$303K
BC icon
339
Brunswick
BC
$5.41B
$381K 0.01%
+3,950
New +$347K
TEVA icon
340
Teva Pharmaceuticals
TEVA
$40.1B
$381K 0.01%
27,000
SNOW icon
341
PUT
Snowflake
SNOW
$110B
$372K 0.01%
2,300
-17,200
-88% -$3.34M
ALKS icon
342
PUT
Alkermes
ALKS
$8.33B
$365K 0.01%
+13,500
New +$383K
RCKT icon
343
CALL
Rocket Pharmaceuticals
RCKT
$376M
$364K 0.01%
+13,500
New +$383K
SNOW icon
344
Snowflake
SNOW
$110B
$364K 0.01%
+2,250
New +$436K
RKT icon
345
CALL
Rocket Companies
RKT
$39.9B
$359K 0.01%
+24,700
New +$307K
CPNG icon
346
Coupang
CPNG
$30.1B
$347K 0.01%
+19,500
New +$319K
VTYX
347
DELISTED
Ventyx Biosciences
VTYX
$342K 0.01%
+62,262
New +$285K
SMTC icon
348
Semtech
SMTC
$12B
$331K 0.01%
+12,047
New +$257K
SFIX
349
Stitch Fix
SFIX
$567M
$321K 0.01%
+121,466
New +$374K
CRVO icon
350
CervoMed
CRVO
$25.9M
$315K 0.01%
+13,500
New +$180K

Similar funds

J. Goldman & Co's Q1 2024 Portfolio in Review

As of Q1 2024, J. Goldman & Co held 560 positions worth $3.1B, up 26% from $2.47B the previous quarter. Its ten largest holdings account for 20% of the portfolio.

J. Goldman & Co deployed $447M of net new capital in Q1 2024, opening 236 new positions and adding to 69 existing holdings. Its largest new stake was Sherwin-Williams: 180,485 shares worth $62.7M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 18% of assets, up from 15% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was PayPal, an estimated $67.6M trimmed.

  • J. Goldman & Co's largest Q1 2024 buy was Sherwin-Williams: 180,485 shares worth $62.7M.
  • J. Goldman & Co added most to eBay in Q1 2024, an estimated $59.6M increase.
  • J. Goldman & Co's biggest Q1 2024 reduction was PayPal, cutting an estimated $67.6M.
  • J. Goldman & Co fully exited MDU Resources in Q1 2024, selling an estimated $36.5M.
  • J. Goldman & Co's ten largest holdings make up 20% of its $3.1B portfolio in Q1 2024.
  • J. Goldman & Co opened 236 new positions and closed 160 in Q1 2024.
  • J. Goldman & Co's portfolio value rose 26% quarter-over-quarter to $3.1B.

Based on J. Goldman & Co's 13F filing for Q1 2024, filed 15 May 2024.